The reduced crosslink softgel market is projected to grow from USD 168.3 million in 2026 to USD 279.4 million by 2036, at a CAGR of 5.2%. Softgel shells low-crosslink will dominate with a 50.0% market share, while nutraceutical delivery will lead the application segment with a 52.0% share.